Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)
2016-001164-11Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of neridronic acid in complex regional pain syndrome (CRPS) and Complex Regional Pain Syndrome Type 1 (CRPS-1), sponsored by Grünenthal GmbH. Primary endpoint: Treatment-emergent adverse events. Started Jan 2017; status: completed.
02
Drugs
neridronic acid
03
Conditions
complex regional pain syndrome (CRPS)Complex Regional Pain Syndrome Type 1 (CRPS-1)
Beyond the preview
Go deeper on 2016-001164-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001164-11.